360 related articles for article (PubMed ID: 35488449)
1. ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Dai Y; Ni S; Wu F; Guo S; Zhao X; Wang J
J Clin Pharm Ther; 2022 Sep; 47(9):1379-1387. PubMed ID: 35488449
[TBL] [Abstract][Full Text] [Related]
2. Different alteration patterns of sub-macular choroidal thicknesses in aquaporin-4 immunoglobulin G antibodies sero-positive neuromyelitis optica spectrum diseases and isolated optic neuritis.
Peng C; Li L; Yang M; Teng D; Wang J; Lai M; Qian H; Li H; Zhou H; Xu Q; Wei S
Acta Ophthalmol; 2020 Dec; 98(8):808-815. PubMed ID: 32657009
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
5. Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.
Zhang J; Chen MJ; Zhao GX; Li HF; Wu L; Xu YF; Liao Y; Yuan Z; Wu ZY
J Neurol; 2021 Feb; 268(2):506-515. PubMed ID: 32862241
[TBL] [Abstract][Full Text] [Related]
6. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks.
Wang Y; Zhong X; Wang H; Peng Y; Shi F; Jia D; Yang H; Zeng Q; Quan C; ZhangBao J; Lee M; Qi J; Chen X; Qiu W;
Eur J Neurol; 2023 Jan; 30(1):195-203. PubMed ID: 36087008
[TBL] [Abstract][Full Text] [Related]
7. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
8. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
10. Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis.
Zhang Y; Bao Y; Qiu W; Peng L; Fang L; Xu Y; Yang H
Exp Eye Res; 2018 Oct; 175():124-132. PubMed ID: 29913164
[TBL] [Abstract][Full Text] [Related]
11. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
12. [Effects of intravenous methylprednisolone pulse therapy on optic neuritis associated with AQP4 antibody seropositive neuromyelitis optica].
Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
Zhonghua Yan Ke Za Zhi; 2019 Mar; 55(3):180-185. PubMed ID: 30841684
[No Abstract] [Full Text] [Related]
13. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica.
Guo S; Jiang H; Jiang L; Peng J; Liu H; Wang J; Wei W
Sci Rep; 2021 Nov; 11(1):22229. PubMed ID: 34782653
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia.
Lalwani CS; Faisal F; Yadav A; Kannoth S; Nambiar V; Gopinath S; Kumar A; Umesh SU; Vincent J; Anoop S; Mathai A; Panicker S
Mult Scler Relat Disord; 2023 Jul; 75():104736. PubMed ID: 37126965
[TBL] [Abstract][Full Text] [Related]
16. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
18. A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG.
Wang X; Chen X; Zhu C; Ma H; Wang F; Qin L; Li W
Medicine (Baltimore); 2018 Nov; 97(48):e13100. PubMed ID: 30508889
[TBL] [Abstract][Full Text] [Related]
19. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
[TBL] [Abstract][Full Text] [Related]
20. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
